查了一下资产负债表,果然2021年商誉从4.42亿增加到9.02亿,这次收购使公司的运营效率大幅下滑,至今未缓过来。
查看全文
SeekingBiotech2022-10-10 23:43
SUPN receives CRL for the SPN-830 NDA/阿扑吗啡注射液/改良新药
$Supernus制药(SUPN)$查看全文
chuminhua2021-10-12 15:29
10月11日,Supernus Pharmaceuticals同意以每股8.10美元的现金,或约4亿美元收购Adamas制药公司,获得两种获准用于帕金森病患者的药物。该交易还包括两项或有价值权(CVR),其总价值为每股1美元的现金,或约5000万美元。最初的现金对价比Adamas公司10月8日的收盘股价溢价约75%。
该交易将为Su...查看全文
Sylviashi20002021-06-08 00:49
//@JZee:回复@美股马甲: $Sage Therapeutics(SAGE)$$Supernus制药(SUPN)$$Axsome Therapeutics(AXSM)$ 。。。//@美股马甲:回复@美股马甲:批了。CNS的狂欢要开始了查看全文
JZee2021-06-07 23:32
回复@美股马甲: $Sage Therapeutics(SAGE)$ $Supernus制药(SUPN)$ $Axsome Therapeutics(AXSM)$ 。。。//@美股马甲:回复@美股马甲:批了。CNS的狂欢要开始了查看全文
chuminhua2021-04-08 15:00
4月2日,Supernus公司宣布,FDA已批准该公司Qelbree(viloxazine缓释胶囊) 上市,用于治疗6-17岁儿童注意力缺陷多动障碍(ADHD)。Qelbree是近10年来FDA批准的首个新型非兴奋剂类ADHD药物。 Qelbree是一种具有选择性5-羟色胺调节活性的去甲肾上腺素再摄取抑制剂(NET),这一药物已在欧洲作为抗抑郁药...查看全文
蹊之美股生物医药2021-04-05 19:45
作者:Kirkland Hwang
微信公众号:蹊之美股生物医药 / CaesarBiotech
标的公司:Supernus Pharmaceuticals Inc.(NASDAQ:SUPN)
• Qelbree(维洛沙嗪缓释胶囊)代表了十年来第一个非刺激性治疗注意力缺陷型多动症(ADHD)的新方法
Supernus制药公司(Supernus Pharmaceutic...查看全文
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-11-06 AccNo: 0001104659-18-066367 Size: 252 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 美东时间 2018-11-06 盘后 披露财报,预期EPS 0.44 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-10-25 AccNo: 0001104659-18-063964 Size: 44 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-21 AccNo: 0001104659-18-057845 Size: 42 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-18 AccNo: 0001104659-18-057416 Size: 59 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-07 AccNo: 0001104659-18-055660 Size: 47 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-04 AccNo: 0001104659-18-055089 Size: 58 KBItem 7.01: Regulation FD DisclosureItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-08-09 AccNo: 0001104659-18-050920 Size: 6 MB 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-08-07 AccNo: 0001104659-18-050207 Size: 266 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Supernus Pharmaceuticals, Inc.(SUPN)$ 美东时间 2018-08-07 盘后 披露财报,预期EPS 0.44 网页链接